Skip to main content
Investors

Company Information

Overview
Press Releases
Events + Presentations
Company Information     
Stock Information
Analyst Coverage
SEC Filings
Corporate Governance
News Alerts

Company Profile

Vallon Pharmaceuticals (NASDAQ: VLON) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel abuse-deterrent medications for CNS disorders. The Company’s lead investigational product candidate, ADAIR (Abuse-Deterrent Amphetamine Immediate-Release), is a proprietary abuse-deterrent formulation of immediate release (IR) dextroamphetamine in development for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. ADAIR is designed to deter attempts to crush and snort and provides barriers to injection. Leveraging the clinical success of dextroamphetamine, we are developing ADAIR through a streamlined 505(b)(2) U.S. FDA regulatory pathway, which is expected to obviate the need for large Phase 2 and Phase 3 efficacy and safety studies. If approved, ADAIR is expected to be the first abuse-deterrent, immediate-release formulation of dextroamphetamine.

Leadership

David Baker, President & CEO
Tim Whitaker, M.D., Chief Medical Officer
Leanne Kelly, Chief Financial Officer

IR Contacts

Investor & Media Relations
Jenene Thomas
JTC IR
vallon@jtcir.com
(833) 475-8247

Transfer Agent
VStock Transfer LLC
l-z@vstocktransfer.com
(212) 828-8436

U.S. Legal Council
Thompson Hine LLP
335 Madison Ave, 12th Floor
New York, NY 10017
(212) 908-3905

Auditor
EisnerAmper
111 Wood Ave S.
Iselin, NJ 08830
(732) 243-7000

Frequently Asked Questions

How is Vallon stock traded?

Vallon stock is traded on NASDAQ under the ticker symbol VLON

Can I buy stock directly from Vallon?

No, you will need to contact a licensed stockbroker or use an online trading account

How do I get my purchased shares?

Contact VStock Transfer LLP  by telephone at (212) 828-8436 or by email at l-z@vstocktransfer.com

What is Vallon’s CUSIP number?

CUSIP # 92023M101

What is Vallon’s industry classification?

Sector: Pharmaceutical Preparations
SIC: 2834

Who can I contact for general information about Vallon?

Where is Vallon’s corporate headquarters?

100 N. 18th Street, Suite 300, Philadelphia, PA 19103

When was Vallon incorporated?

Vallon was incorporated in the state of Delaware on January 11, 2018 and completed its organization, formation, and initial capitalization activities effective as of June 7, 2018

When is Vallon’s fiscal year end?

December 31

Who are Vallon’s independent auditors?

EisnerAmper

Who is Vallon’s outside legal counsel?

Thompson Hine LLP

© 2023 Vallon Pharmaceuticals | Terms of Use | Privacy Policy

ADAIR is an investigational new drug product and has not yet been approved by the FDA. All trademarks shown are the property of their respective owners.

David Baker

President & CEO

David is a co-founder of Vallon and has over 25 years of executive, operational and commercial leadership experience in the biopharmaceutical industry. He has been directly involved with the commercialization of five medications with annual sales in excess of $1 billion each, including Adderall XR® and Vyvanse®, the two most successful ADHD brands based on annual revenue. Previously, David was the Chief Commercial Officer and interim CEO of Alcobra Ltd., a CNS specialty pharmaceutical company that completed a reverse merger with Arcturus Therapeutics in late 2017. Prior to Alcobra, he worked at Shire Plc for 10 years as Vice President of Commercial Strategy and New Business in the Neuroscience Business Unit, Global General Manager for Vyvanse® and Vice President, ADHD Marketing. Prior to Shire, he worked at Merck & Co. in marketing, sales, market research, and business development. Mr. Baker's therapeutic expertise includes ADHD, autism, osteoporosis, migraine, and hyperlipidemia. Mr. Baker earned a bachelor’s degree in Economics and Computer Science from Duke University, and an MBA in Marketing, from Duke’s Fuqua School of Business.

LinkedIn

Timothy Whitaker, M.D.

Chief Medical Officer

Tim brings over 20 years of experience in the pharmaceutical industry and nearly a decade in academic medicine. His pharmaceutical industry experience involves extensive leadership and management of many global clinical development programs, achieving numerous global regulatory approvals. The majority of his work has been in neuroscience and includes leading the development and approval of multiple ADHD medications. Most recently, Tim served as the Chief Medical Officer at Alder Biopharmaceuticals leading a positive Phase III study in the development of a CGRP antagonist for migraine. Prior to that, Tim worked at Shire for more than 10 years, most recently as VP and Neuroscience Therapeutic Area Head, Global Clinical Development. Prior to Shire, Tim served as a Senior Director – Neuroscience at Wyeth Research with a focus on sleep disorders and life cycle management for Effexor®. Prior to joining the industry, Tim held a variety of clinical and teaching positions at the University of Vermont (UVM) College of Medicine and the Medical Center Hospital of Vermont, including Associate Professor of Psychiatry, Director of the Inpatient Services, Executive Committee of the Vermont Regional Sleep Disorders Center, and Director of the Psychopharmacology Clinic. He earned his bachelor’s degree from Duke University, and his medical degree from Wake Forest University School of Medicine. He completed a residency training program in psychiatry and a fellowship in clinical psychopharmacology at UVM/Medical Center Hospital of Vermont in Burlington.

LinkedIn

Leanne Kelly

Chief Financial Officer

Ms. Kelly is an accomplished financial executive with over 20 years of experience leading private and publicly traded companies across life science, technology and e-Commerce sectors and a foundation in public accounting. Prior to joining Vallon, she most recently served as the Controller and Executive Director, Global Financial Reporting at OptiNose, Inc. (NASDAQ: OPTN), a $50M revenue specialty pharmaceutical company. Over the course of her career, she has held Senior Vice President of Finance, Controller and Chief Financial Officer positions in private and public companies such as Flower Orthopedics, Iroko Pharmaceuticals, LLC, and Genaera Corporation. Ms. Kelly began her career as an auditor with KPMG LLP. While serving in those roles, Ms. Kelly's work included multi-million dollar financings, M&A diligence and support. She also has experience in financial oversight, internal and external financial reporting, forecasting, and financial analysis, as well as investor and public relations. Ms. Kelly received her Bachelor of Science degree in Business Economics with a concentration in Accounting from Lehigh University, and is a licensed CPA (inactive status) in the state of Pennsylvania.

LinkedIn